Scalper1 News
Ethical drugmakers did well Monday after a big merger was finally consummated in the space. Actavis (ACT) emerged the winner in the Allergan (AGN) takeover battle. It agreed to buy the Botox maker for $66 billion in cash and stock. The deal values Allergan at around 219 a share — significantly higher than Valeant Pharmaceuticals’ (VRX) offer, which valued Allergan around 175. Bill Ackman-backed Valeant had been trying to acquire Allergan since Scalper1 News
Scalper1 News